{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:32:27Z","timestamp":1783463547328,"version":"3.55.0"},"reference-count":40,"publisher":"The Royal Society","issue":"1433","license":[{"start":{"date-parts":[[2003,5,29]],"date-time":"2003-05-29T00:00:00Z","timestamp":1054166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Phil. Trans. R. Soc. Lond. B"],"published-print":{"date-parts":[[2003,5,29]]},"abstract":"<jats:p>\n                    Glycosphingolipid (GSL) lysosomal storage disorders are inherited enzyme deficiencies that result in pathological lysosomal accumulation of glycolipids, with widespread clinical consequences. Type 1 Gaucher disease is the commonest of these; the deficient enzyme in this condition is glucocerebrosidase. Clinical manifestations include hepatosplenomegaly, thrombocytopenia, anaemia, recurrent infections and skeletal lesions. The condition can be treated with intravenous enzyme replacement therapy (ERT). Substrate reduction therapy is a new approach in which glycolipid accumulation is counteracted not by replacing the deficient enzyme but by reducing the substrate level to better balance residual activity of the deficient enzyme. Miglustat is an inhibitor of glucosylceramide synthase, a key enzyme in GSL synthesis. Oral administration of miglustat to patients with type 1 Gaucher disease attenuates the synthesis of glucocerebroside, the substrate of the deficient glucocerebrosidase. In the first clinical study, patients with type 1 Gaucher disease who had enlargement of the liver or spleen and (if present) the spleen at baseline received 12 months treatment with oral miglustat. There were mean decreases in liver and spleen volumes of 12% (7.9\u201316.4,\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001) and 19% (14.3\u201323.7,\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001), respectively. Mean haemoglobin increased by 0.26 g dl\n                    <jats:sup>\u22121<\/jats:sup>\n                    (\u22120.5\u22120.57, not statistically significant) and platelet count by 8.3 \u00d7 10\n                    <jats:sup>9<\/jats:sup>\n                    l\n                    <jats:sup>\u22121<\/jats:sup>\n                    (1.9\u201314.7,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.014).\n                  <\/jats:p>","DOI":"10.1098\/rstb.2003.1271","type":"journal-article","created":{"date-parts":[[2003,9,9]],"date-time":"2003-09-09T11:27:32Z","timestamp":1063106852000},"page":"955-960","source":"Crossref","is-referenced-by-count":31,"title":["Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease"],"prefix":"10.1098","volume":"358","author":[{"given":"Chris","family":"Moyses","sequence":"first","affiliation":[{"name":"Oxford GlycoSciences, The Forum, 86 Milton Park, Abingdon, Oxford OX14 4RY, UK()"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2003,5,29]]},"reference":[{"key":"p_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(97)80034-0"},{"key":"p_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2003.1273"},{"key":"p_3","doi-asserted-by":"publisher","DOI":"10.1002\/elps.1150191103"},{"key":"p_4","unstructured":"Anon. 1998 Profiting from proteomics: strategies and technologies. London: PJB."},{"key":"p_5","unstructured":"Barranger J. A. & Ginns E. I. 1989 Glucosylceramide lipidoses: Gaucher's Disease. In The metabolic basis of inherited disease (ed. C. R. Scriver A. L. Beaudet S. W. Sly & D. Valle) pp. 1677-1698. New York: McGraw-Hill."},{"key":"p_6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242104"},{"key":"p_7","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(97)80038-8"},{"key":"p_8","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1995.0012"},{"key":"p_9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2235"},{"key":"p_10","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(97)80031-5"},{"key":"p_11","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2003.1269"},{"key":"p_12","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2003.1278"},{"key":"p_13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"p_14","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.7.483"},{"key":"p_15","first-page":"139","article-title":"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells\/mm3","volume":"7","author":"Fischl M. A.","year":"1994","journal-title":"J. Acquired Immune Deficiency Syndrome"},{"key":"p_16","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1128\/JVI.69.9.5791-5797.1995","article-title":"The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding","volume":"69","author":"Fischer P. B.","year":"1995","journal-title":"J. Virol."},{"key":"p_17","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1128\/JVI.70.10.7143-7152.1996","article-title":"N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1\/V2 region of gp120","volume":"70","author":"Fischer P. B.","year":"1996","journal-title":"J. Virol."},{"key":"p_18","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(88)80185-6"},{"key":"p_19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-1-199501010-00005"},{"key":"p_20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117084"},{"key":"p_21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91037-9"},{"key":"p_22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.11.6388"},{"key":"p_23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0021-9258(18)54189-2","article-title":"Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120","volume":"268","author":"Karlsson G. B.","year":"1993","journal-title":"J. Biol. Chem."},{"key":"p_24","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.3.455"},{"key":"p_25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","article-title":"Enzyme therapy in Gaucher disease Type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months","volume":"82","author":"Pastores G. M.","year":"1993","journal-title":"Blood"},{"key":"p_26","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0498-393"},{"key":"p_27","doi-asserted-by":"publisher","DOI":"10.1021\/bi000107z"},{"key":"p_28","first-page":"421","article-title":"New therapeutic prospects for the glycosphingolipid lysosomal storage diseases","volume":"56","author":"Platt F. M.","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"p_29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1992.tb17173.x"},{"key":"p_30","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt F. M.","year":"1994","journal-title":"J. Biol. Chem."},{"key":"p_31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.31.19365"},{"key":"p_32","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5311.428"},{"key":"p_33","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2003.1279"},{"key":"p_34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1998.tb00145.x"},{"key":"p_35","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199510050-00008"},{"key":"p_36","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(91)90066-I"},{"key":"p_37","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005367328003"},{"key":"p_38","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90042-6"},{"key":"p_39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91038-7"},{"key":"p_40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.21.11878"}],"container-title":["Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2003.1271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2003.1271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:22:09Z","timestamp":1778620929000},"score":1,"resource":{"primary":{"URL":"http:\/\/royalsocietypublishing.org\/rstb\/article\/358\/1433\/955-960\/20192"}},"subtitle":[],"editor":[{"given":"R. A.","family":"Dwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"T. D.","family":"Butters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"F. M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"T. M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,5,29]]},"references-count":40,"journal-issue":{"issue":"1433","published-print":{"date-parts":[[2003,5,29]]}},"alternative-id":["10.1098\/rstb.2003.1271"],"URL":"https:\/\/doi.org\/10.1098\/rstb.2003.1271","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,29]]}}}